Hemos leído sobre ... Esclerodermia

Última actualización: 3 junio 2024
MAYO 2024
  • Tirelli F, Zanatta E, Moccaldi B, Binda M, Martini G, Giraudo C, et al.
    Systemic sclerosis sine scleroderma in children is more aggressive than in adults.
    Rheumatology (Oxford). 2024 May 22:keae304. doi: 10.1093/rheumatology/keae304.

  • Türkmen Ş, Pirim G, Sözeri B.
    Ultrasonographic Evaluation of Juvenile Localized Scleroderma: Enhancing Objectivity in Diagnosis and Management.
    Curr Med Imaging. 2024 May 24. doi: 10.2174/0115734056299155240516102231.

ABRIL 2024
  • Kose H, Simsek A, Kizmaz MA, Bozkurt T, Ozturk F, Cekic S, et al.
    Interferons Dominate Damage and Activity in Juvenile Scleroderma.
    Mod Rheumatol. 2024 Apr 6:roae032. doi: 10.1093/mr/roae032. Online ahead of print.

MARZO 2024
  • Knobler R, Geroldinger-Simić M, Kreuter A, Hunzelmann N, Moinzadeh P, Rongioletti F, et al.
    Consensus statement on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: Localized scleroderma, systemic sclerosis and overlap syndromes.
    J Eur Acad Dermatol Venereol. 2024 Mar 8. doi: 10.1111/jdv.19912. Online ahead of print.

  • Kreuter A, Moinzadeh P, Kinberger M, Horneff G, Worm M, Werner RN, et al.
    S2k guideline: Diagnosis and therapy of localized scleroderma.
    J Dtsch Dermatol Ges. 2024 Mar 1. doi: 10.1111/ddg.15328. Online ahead of print.

  • Morrisroe K, Hansen D, Stevens W, Ross L, Sahhar J, Ngian GS, et al.
    Predictors and prognosis of pulmonary hypertension complicating interstitial lung disease in systemic sclerosis.
    Rheumatology (Oxford). 2024 Mar 12:keae166. doi: 10.1093/rheumatology/keae166. Online ahead of print.

  • Erdogan M, Kilickiran Avci B, Ebren C, Ersoy Y, Ongen Z, Ongen G, et al.
    Screening for pulmonary arterial hypertension in patients with systemic sclerosis in the era of new pulmonary arterial hypertension definitions.
    Clin Exp Rheumatol. 2024 Mar 15. doi: 10.55563/clinexprheumatol/gzo4r2. Online ahead of print.

  • Channick R, Chin KM, McLaughlin VV, Lammi MR, Zamanian RT, Turricchia S, 
    Macitentan in Pulmonary Arterial Hypertension Associated with Connective Tissue Disease (CTD-PAH): Real-World Evidence from the Combined OPUS/OrPHeUS Dataset.
    Cardiol Ther. 2024 Mar 7. doi: 10.1007/s40119-024-00361-w. Online ahead of print.

  • Thammaroj P, Chowchuen P, Foocharoen C.
    Clinical course and factors associated with progressive acro-osteolysis in early systemic sclerosis: a retrospective cohort study.
    Sci Rep. 2024 Mar 1;14(1):5129. doi: 10.1038/s41598-024-55877-x.

  • Stubbs LA, Ogunbona O, Beil E, Szafron V, Adesina A, Anvari S, Lai J, Ramirez A, Ditzler MG, DeGuzman M.
    Juvenile eosinophilic fasciitis: a single center case series.
    Pediatr Rheumatol Online J. 2024 Feb 24;22(1):29. doi: 10.1186/s12969-024-00960-w.

ENERO 2024
  • Terminiello A, Marrani E, Pagnini I, Maccora I, Maniscalco V, Rumeileh SA, Mastrolia MV, Simonini G.
    Childhood mixed connective tissue disease at disease onset: Evidence from a systematic review.
    Autoimmun Rev. 2024 Jan 6;23(4):103513. doi: 10.1016/j.autrev.2023.103513. Epub ahead of print.

  • Akbaş A, Kılınç F, Hayran Y.
    A Comparison of Clinical, Demographic and Treatment Characteristics of Pediatric-Onset and Adult-Onset Patients Diagnosed With Localized Scleroderma.
    Dermatol Pract Concept. 2024 Jan 1;14(1):e2024023. doi: 10.5826/dpc.1401a23.

  • Tornling G, Edenius C, Pauling JD, Denton CP, Olsson A, Kowalski J, et al.
    A phase 2 trial investigating the efficacy and safety of the mPGES-1 inhibitor vipoglanstat in systemic sclerosis-related Raynaud's.
    Rheumatology (Oxford). 2024 Jan 30:keae049. doi: 10.1093/rheumatology/keae049. Online ahead of print.

  • Herrick AL, Orozco G.
    Raynaud phenomenon: from GWAS to drug repurposing.
    Nat Rev Rheumatol. 2024 Jan 16. doi: 10.1038/s41584-024-01076-x. Epub ahead of print.

  • Foeldvari I, Torok KS, Antón J, Blakley M, Constantin T, Cutolo M, et al.
    Best clinical practice in the treatment of juvenile systemic sclerosis: expert panel guidance - the result of the International Hamburg Consensus Meeting December 2022.
    Expert Rev Clin Immunol. 2023 Dec 27:1-18. doi: 10.1080/1744666X.2023.2298354. Epub ahead of print.

  • Foeldvari I, Torok KS, Anton J, Blakley M, Constantin T, Curran M, et al.
    Proposed Response Parameters for Twelve-Month Drug Trial in Juvenile Systemic Sclerosis: Results of the Hamburg International Consensus Meetings.
    Arthritis Care Res (Hoboken). 2023 Dec;75(12):2453-2462. doi: 10.1002/acr.25171.

  • Tirelli F, Giraudo C, Soliani M, Calabrese F, Martini G, Gisondi P, Meneghel A, Zulian F.
    Connective tissue nevus misdiagnosed as juvenile localized scleroderma
    Pediatr Rheumatol Online J. 2023 Oct 17;21(1):125. doi: 10.1186/s12969-023-00913-9.

  • Sanchez-Espino LF, Luca N, Pope E, Laxer RM, Knight AM, Sibbald C.
    Systematic review of health-related quality of life impact in juvenile localized scleroderma: Health-related quality of life in juvenile localized scleroderma.
    Arthritis Care Res (Hoboken). 2023 Sep 26. doi: 10.1002/acr.25243. Online ahead of print.

  • Bass RD, Moore DF, Steen VD.
    Prevalence and Characteristics of Systemic Sclerosis Patients Fulfilling the 2019 EULAR/ACR Classification Criteria for Systemic Lupus Erythematosus.
    Arthritis Care Res (Hoboken). 2023 Sep 10. doi: 10.1002/acr.25235. Online ahead of print.

  • Campochiaro C, Allanore Y, Braun-Moscovici Y, Matucci-Cerinic M, Balbir-Gurman A.
    Is cyclophosphamide still the gold standard in early severe rapidly progressive systemic sclerosis?
    Autoimmun Rev. 2023 Sep 9:103439. doi: 10.1016/j.autrev.2023.103439. Online ahead of print.

  • Tandaipan J, Guillén-Del-Castillo A, Simeón-Aznar CP, Carreira PE, De la Puente C, Narváez J, et al.
    Immunoglobulins in systemic sclerosis management. A large multicenter experience.
    Autoimmun Rev. 2023 Sep 12;22(11):103441. doi: 10.1016/j.autrev.2023.103441. Online ahead of print.

  • Di Battista M, Wasson CW, Alcacer-Pitarch B, Del Galdo F.
    Autonomic dysfunction in systemic sclerosis: A scoping review.
    Semin Arthritis Rheum. 2023 Sep 26;63:152268. doi: 10.1016/j.semarthrit.2023.152268. Online ahead of print.

  • Joly-Chevrier M, Gélinas A, Ghazal S, Moussa S, McCuaig CC, Piram M, et al.
    Morphea, Eosinophilic Fasciitis and Cancer: A Scoping Review.
    Cancers (Basel). 2023 Sep 7;15(18):4450. doi: 10.3390/cancers15184450.

  • Pain CE, Murray A, Dinsdale G, Marsden A, Manning J, Riley P, Leone V, Amin T, Zulian F, Herrick AL.
    Non-invasive imaging and clinical skin scores in juvenile localised scleroderma.
    Rheumatology (Oxford). 2023 Aug 2:kead380. doi: 10.1093/rheumatology/kead380. Epub ahead of print.

  • De Angelis R, Riccieri V, Cipolletta E, Del Papa N, Ingegnoli F, Bosello S, et al.
    Significant nailfold capillary loss and late capillaroscopic pattern are associated with pulmonary arterial hypertension in systemic sclerosis.
    Rheumatology (Oxford). 2023 Aug 25:kead445. doi: 10.1093/rheumatology/kead445. Online ahead of print.

MAYO 2023
  • Chen HW, Walker AM, Stein AB, Chen SL, Schollaert-Fitch KL, Torok KS, Jacobe HT.
    Clinical characteristics associated with musculoskeletal extracutaneous manifestations in pediatric and adult morphea: a prospective, cohort study.
    J Invest Dermatol. 2023 May 2:S0022-202X(23)02042-0. doi: 10.1016/j.jid.2023.04.010. Epub ahead of print.

  • Wang S, Berry CT, Treat JR, Jen M.
    Morphea after initiation of dupilumab in two pediatric atopic dermatitis patients.
    Pediatr Dermatol. 2023 May-Jun;40(3):540-543. doi: 10.1111/pde.15200. Epub 2022 Nov 22.

ABRIL 2023
  • Stubbs LA, Ferry AM, Guffey D, Loccke C, Wade EM, Pour P, Ardalan K, Chira P, Ganske IM, Glaser D, Higgins G, Luca N, Moore KF, Sivaraman V, Stewart K, Vasquez-Canizares N, Hunt RD, Maricevich RS, Torok KS, Li SC; Childhood Arthritis, Rheumatology Research Alliance (CARRA) Scleroderma Workgroup.
    Barriers to care in juvenile localized and systemic scleroderma: an exploratory survey study of caregivers' perspectives
    Pediatr Rheumatol Online J. 2023 Apr 25;21(1):39. doi: 10.1186/s12969-023-00819-6.

MARZO 2023
  • Mulcaire-Jones E, Low AHL, Domsic R, Whitfield ML, Khanna D.
    Advances in biological and targeted therapies for systemic sclerosis.
    Expert Opin Biol Ther. 2023 Mar 25. doi: 10.1080/14712598.2023.2196009. Online ahead of print.

  • Makol A, Nagaraja V, Amadi C, Pugashetti JV, Caoili E, Khanna D.
    Recent innovations in the screening and diagnosis of systemic sclerosis-associated interstitial lung disease.
    Expert Rev Clin Immunol. 2023 Mar 31. doi: 10.1080/1744666X.2023.2198212. Online ahead of print.

  • Ciaffi J, Liem SIE, van Leeuwen NM, Allaart CF, Huizinga TWJ, de Vries-Bouwstra JK.
    Comment on: Glucocorticoids prescribing practices in systemic sclerosis: an analysis of the EUSTAR database.
    Rheumatology (Oxford). 2023 Mar 21:kead120. doi: 10.1093/rheumatology/kead120. Online ahead of print.

  • De Angelis R, Ferri C, Giuggioli D, Bajocchi G, Dagna L, Bellando-Randone S, et al; SPRING-SIR (Systemic Sclerosis PRogression INvestiGation group of the Italian Society of Rheumatology).
    Systemic sclerosis sine scleroderma: clinical and serological features and relationship with other cutaneous subsets in a large series of patients from the national registry 'SPRING' of the Italian Society
    or Rheumatology.
    RMD Open. 2023 Mar;9(1):e002890. doi: 10.1136/rmdopen-2022-002890.

  • Fukasawa T, Yoshizaki A, Ebata S, Fukayama M, Kuzumi A, Norimatsu Y, et al.
    Interleukin-17 pathway inhibition with brodalumab in early systemic sclerosis: analysis of a single-arm, open-label, phase 1 trial.
    J Am Acad Dermatol. 2023 Mar 28:S0190-9622(23)00516-9. doi: 10.1016/j.jaad.2023.02.061. Online ahead of print.

  • Lagziel T, Kawaji Q, Hultman CS.
    Incisional Release and Fat Grafting for the Surgical Management of Perioral Fibrosis in Scleroderma: A Technical Report and Institutional Review
    Ann Plast Surg. 2023 Feb 4. doi: 10.1097/SAP.0000000000003475. Online ahead of print.

  • Kardum Ž, Milas-Ahić J, Šahinović I, Masle AM, Uršić D, Kos M.
    Serum levels of interleukin 17 and 22 in patients with systemic sclerosis: a single-center cross-sectional study.
    Rheumatol Int. 2023 Feb;43(2):345-354. doi: 10.1007/s00296-022-05250-w.

ENERO 2023
  • Giannini M, Ellezam B, Leclair V, Lefebvre F, Troyanov Y, Hudson M, et al.
    Scleromyositis: A distinct novel entity within the systemic sclerosis and autoimmune myositis spectrum. Implications for care and pathogenesis.
    Front Immunol. 2023 Jan 26;13:974078. doi: 10.3389/fimmu.2022.974078.

  • Mazilu D, Boltașiu Tătaru LA, Mardale DA, Bijă MS, Ismail S, Zanfir V, et al
    Eosinophilic Fasciitis: Current and Remaining Challenges.
    Int J Mol Sci. 2023 Jan 19;24(3):1982. doi: 10.3390/ijms24031982.

JULIO 2022
  • Garaiman A, Steigmiller K, Gebhard C, Mihai C, Dobrota R, Bruni C, et al; EUSTAR Collaborators
    Use of platelet inhibitors for digital ulcers related to systemic sclerosis: EUSTAR study on derivation and validation of the DU-VASC model.
    Rheumatology (Oxford). 2022 Jul 29:keac405. doi: 10.1093/rheumatology/keac405. Online ahead of print.

  • Vigneron C, Pène F, Charpentier J, Mouthon L, Chaigne B.
    Scleroderma cardiac crisis: A-life-threatening but reversible complication of systemic sclerosis.
    Autoimmun Rev. 2022 Jul 31;21(10):103162. doi: 10.1016/j.autrev.2022.103162. Online ahead of print.

  • Santiago T, Santos EJF, Ruaro B, Lepri G, Green L, Wildt M, et al.
    Recommendations for the execution and reporting of skin ultrasound in systemic sclerosis: an international collaboration under the WSF skin ultrasound group.
    RMD Open. 2022 Jul;8(2):e002371. doi: 10.1136/rmdopen-2022-002371.

  • Ferri C, De Angelis R, Giuggioli D, Bajocchi G, Dagna L, Zanframundo G, et al. SPRING-SIR (Systemic Sclerosis PRogression INvestiGation group of the Italian Society of Rheumatology).
    Geographical heterogeneity of clinical and serological phenotypes of systemic sclerosis observed at tertiary referral centres. The experience of the Italian SIR-SPRING registry and review of the world literature.
    Autoimmun Rev. 2022 Jul 28;21(10):103159. doi: 10.1016/j.autrev.2022.103159. Online ahead of print.

MAYO 2022
  • Cai R, Yi Z, Li T, Mu R.
    Botulinum toxin in the treatment of Raynaud phenomenon in patients with systemic sclerosis: a systemic review.
    Chin Med J (Engl). 2022 May 5;135(9):1133-1134. doi: 10.1097/CM9.0000000000001903.

  • Hofmann NN, Ambühl RA, Jordan S, Distler O.
    Calcineurin inhibitors in systemic sclerosis - a systematic literature review.
    Ther Adv Musculoskelet Dis. 2022 May 19;14:1759720X221092374. doi: 10.1177/1759720X221092374.

  • Kreuter M, Hoffmann-Vold AM, Matucci-Cerinic M, Saketkoo LA, Highland KB, Wilson H, Alves M, et al.
    Impact of lung function and baseline clinical characteristics on patient-reported outcome measures in systemic sclerosis-associated interstitial lung disease.
    Rheumatology (Oxford). 2022 May 31:keac325. doi: 10.1093/rheumatology/keac325. Online ahead of print.
MARZO 2022
  • Foocharoen C, Tonsawan P, Pongkulkiat P, Anutrakulchai S, Mahakkanukrauh A, Suwannaroj S.
    Management Review of Scleroderma Renal Crisis: An Update with Practical pointers.
    Mod Rheumatol. 2022 Mar 29:roac028. doi: 10.1093/mr/roac028. Online ahead of print.

  • Isomura Y, Shirai Y, Kuwana M.
    Clinical worsening following discontinuation of tocilizumab in diffuse cutaneous systemic sclerosis: a single-centre experience in Japan.
    Rheumatology (Oxford). 2022 Mar 8:keac136. doi: 10.1093/rheumatology/keac136. Online ahead of print

  • McGaugh S, Kallis P, De Benedetto A, Thomas RM.
    Janus kinase inhibitors for treatment of morphea and systemic sclerosis: A literature review.
    Dermatol Ther. 2022 Mar 12:e15437. doi: 10.1111/dth.15437. Online ahead of print.

  • Scofield RH, Lewis VM, Cavitt J, Kurien BT, Assassi S, Martin J, et al.
    47XXY and 47XXX in Scleroderma and Myositis.
    ACR Open Rheumatol. 2022 Mar 29. doi: 10.1002/acr2.11413. Online ahead of print.

  • Bartosz M, Tworek M, Łapczyńska E, Tekielak A, Kochanowska J, Polak K, Bergler-Czop B.
    Utility of phototherapy in patients with systemic sclerosis: systematic review.
    Dermatol Ther. 2022 Mar 31:e15478. doi: 10.1111/dth.15478. Online ahead of print.

  • Cui J, Jin L, Ding M, He J, Yang L, Cui S, Wang X, Ma J, Liu A.
    Efficacy and safety of mesenchymal stem cells in the treatment of systemic sclerosis: a systematic review and meta-analysis.
    Stem Cell Res Ther. 2022 Mar 21;13(1):118. doi: 10.1186/s13287-022-02786-3.

  • Zanatta E, Huscher D, Ortolan A, Avouac J, Airò P, Balbir-Gurman A, et al; EUSTAR collaborators.
    Phenotype of limited cutaneous systemic sclerosis patients with positive anti-topoisomerase I antibodies: data from EUSTAR cohort.
    Rheumatology (Oxford). 2022 Mar 28:keac188. doi: 10.1093/rheumatology/keac188. Online ahead of print.

  • Xiong A, Liu Q, Zhong J, Cao Y, Xiang Q, Hu Z, Zhou S, Song Z, Chen H, Zhang Y, Cui H, Shuai S.
    Increased risk of mortality in systemic sclerosis-associated pulmonary hypertension: a systemic review and meta-analysis.
    Adv Rheumatol. 2022 Mar 30;62(1):10. doi: 10.1186/s42358-022-00239-2.

  • Bruni C, Heidenreich S, Duenas A, Hoffmann-Vold AM, Gabrielli A, Allanore Y, et al.
    Patient preferences for the treatment of systemic sclerosis-associated interstitial lung disease: a discrete choice experiment.
    Rheumatology (Oxford). 2022 Mar 3:keac126. doi: 10.1093/rheumatology/keac126. Online ahead of print.

  • Kuwana M, Saito A, Sakamoto W, Raabe C, Saito K.
    Incidence Rate and Prevalence of Systemic Sclerosis and Systemic Sclerosis-Associated Interstitial Lung Disease in Japan: Analysis Using Japanese Claims Databases.
    Adv Ther. 2022 Mar 22. doi: 10.1007/s12325-022-02078-5. Online ahead of print.

  • Castelino FV, VanBuren JM, Startup E, Assassi S, Bernstein EJ, Chung L, Correia C, Evnin LB, Frech TM, Gordon JK, Hant FN, Hummers LK, Khanna D, Sandorfi N, Shah AA, Shanmugam VK, Steen V.
    Baseline characteristics of systemic sclerosis patients with restrictive lung disease in a multi-center US-based longitudinal registry.
    Int J Rheum Dis. 2022 Feb;25(2):163-174. doi: 10.1111/1756-185X.14253. 

ENERO 2022
  • Furusawa A, Wakiguchi H, Okazaki F, Korenaga Y, Azuma Y, Yasudo H, Hasegawa S.
    Successful treatment of children with juvenile systemic sclerosis using mycophenolate mofetil after methylprednisolone pulse therapy: A 3-year follow-up.
    Int J Rheum Dis. 2022 Jan;25(1):95-96. doi: 10.1111/1756-185X.14260.

  • Szczepanik-Kułak P, Michalak-Stoma A, Krasowska D.
    Usefulness of Dermoscopy in Localized Scleroderma (LoS, Morphea) Diagnosis and Assessment-Monocentric Cross-Sectional Study.
    J Clin Med. 2022 Jan 30;11(3):764. doi: 10.3390/jcm11030764.

  • Wenzel D, Haddadi NS, Afshari K, Richmond JM, Rashighi M.
    Upcoming treatments for morphea.
    Immun Inflamm Dis. 2021 Dec;9(4):1101-1145. doi: 10.1002/iid3.475. Epub 2021 Jul 17.

  • Li SC, Higgins GC, Chen M, Torok KS, Rabinovich CE et al.
    Extracutaneous involvement is common and associated with prolonged disease activity and greater impact in juvenile localized scleroderma.
    Rheumatology (Oxford). 2021 Dec 1;60(12):5724-5733. doi: 10.1093/rheumatology/keab238.

  • Becker MO, Dobrota R, Garaiman A, Debelak R, Fligelstone K, Tyrrell Kennedy A et al.
    Development and validation of a patient-reported outcome measure for systemic sclerosis: the EULAR Systemic Sclerosis Impact of Disease (ScleroID) questionnaire.
    Ann Rheum Dis. 2021 Nov 25:annrheumdis-2021-220702. doi: 10.1136/annrheumdis-2021-220702. Online ahead of print.

  • Castelino FV, VanBuren JM, Startup E, Assassi S, Bernstein EJ, Chung L et al.
    Baseline characteristics of systemic sclerosis patients with restrictive lung disease in a multi-center US-based longitudinal registry.
    Int J Rheum Dis. 2021 Nov 28. doi: 10.1111/1756-185X.14253. Online ahead of print.

  • Diaconu AD, Ostafie I, Ceasovschih A, Șorodoc V, Lionte C, Ancuța C, Șorodoc L.
    Role of Vitamin D in Systemic Sclerosis: A Systematic Literature Review.
    J Immunol Res. 2021 Nov 29;2021:9782994. doi: 10.1155/2021/9782994.

  • Vonk MC, Smith V, Sfikakis PP, Cutolo M, Del Galdo F, Seibold JR.
    Pharmacological treatments for SSc-ILD: Systematic review and critical appraisal of the evidence.
    Autoimmun Rev. 2021 Oct 27:102978. doi: 10.1016/j.autrev.2021.102978. Online ahead of print.

  • Chung MP, Valenzuela A, Li S, Catanese B, Stevens K, Fiorentino D, Strand V, Chung L.
    A Pilot Study to Evaluate the Safety and Efficacy of Treprostinil in the Treatment of Calcinosis in Systemic Sclerosis.
    Rheumatology (Oxford). 2021 Oct 29:keab810. doi: 10.1093/rheumatology/keab810. Online ahead of print.

  • Zulian F, Lanzoni G, Castaldi B, Meneghel A, Tirelli F, Zanatta E, Martini G.
    Systemic sclerosis sine scleroderma in children.
    Rheumatology (Oxford). 2021 Oct 4:keab738. doi: 10.1093/rheumatology/keab738. Online ahead of print

  • Ulc E, Rudnicka L, Waśkiel-Burnat A, Warszawik-Hendzel O, Niemczyk A, Olszewska M.
    Therapeutic and Reconstructive Management Options in Scleroderma (Morphea) en Coup de Sabre in Children and Adults. A Systematic Literature Review.
    J Clin Med. 2021 Sep 29;10(19):4517. doi: 10.3390/jcm10194517.

  • Kondoh Y, Makino S, Ogura T, Suda T, Tomioka H, Amano H, et al; joint committee of Japanese Respiratory Society and Japan College of Rheumatology.
    2020 guide for the diagnosis and treatment of interstitial lung disease associated with connective tissue disease
    Respir Investig. 2021 Sep 30:S2212-5345(21)00082-4. doi: 10.1016/j.resinv.2021.04.011. Online ahead of print.

  • Zhang Y, Qin D, Li Q, Yang X, Luo Q, Wang H.
    Diagnostic value of cardiac natriuretic peptide on pulmonary hypertension in systemic sclerosis: a systematic review and meta-analysis.
    Joint Bone Spine. 2021 Sep 30:105287. doi: 10.1016/j.jbspin.2021.105287. Online ahead of print

  • Hixon AM, Christensen E, Hamilton R, Drees C.
    Epilepsy in Parry-Romberg syndrome and linear scleroderma en coup de sabre: Case series and systematic review including 140 patients.
    Epilepsy Behav. 2021 Aug;121(Pt A):108068. doi: 10.1016/j.yebeh.2021.108068. 

  • Shenavandeh S S, Ajri M, Hamidi S.
    Causes of Raynaud's phenomenon and the predictive laboratory and capillaroscopy features for the evolution to a definite connective tissue disease.
    Rheumatology (Oxford). 2021 Aug 31:keab668. doi: 10.1093/rheumatology/keab668. Online ahead of print.

  • Flavahan NA.
    New mechanism-based approaches to treating and evaluating the vasculopathy of scleroderma.
    Curr Opin Rheumatol. 2021 Aug 16. doi: 10.1097/BOR.0000000000000830. Online ahead of print.

  • Sibeoni J, Dunogué B, Dupont A, Haiddar D, Benmostefa N, Falissard B, Mouthon L, Révah-Levy A, Verneuil L.
    Development and validation of a Patient-Reported Outcome in systemic sclerosis: the Hand scleroDerma lived Experience Scale (HAnDE Scale).
    Br J Dermatol. 2021 Aug 6. doi: 10.1111/bjd.20688. Online ahead of print.

JULIO 2021
  • Baumberger R, Jordan S, Distler O, Baschung Pfister P, Maurer B.
    Diagnostic measures for patients with systemic sclerosis-associated myopathy.
    Clin Exp Rheumatol. 2021 Jul-Aug;39 Suppl 131(4):85-93. Epub 2021 Jul 15.

  • Verardi L, Calandriello L, De Lorenzis E, Natalello G, Gigante L, Cicchetti G, Larici AR, Gremese E, D'Agostino MA, Bosello SL.
    An unusual lung involvement in scleroderma: lipoid pneumonia.
    Clin Exp Rheumatol. 2021 Jul-Aug;39 Suppl 131(4):161-162.

MAYO 2021
  • Hurtubise R, Hudson M, Gyger G, Wang M, Steele RJ, Baron M; Canadian Scleroderma Research Group (CSRG), Hoa S.
    Association between gastroprotective agents and risk of incident interstitial lung disease in systemic sclerosis.
    Respir Med. 2021 May 27;185:106482. doi: 10.1016/j.rmed.2021.106482. Online ahead of print.

  • Foeldvari I, Torok KS.
    Review for best practice in clinical rheumatology juvenile systemic sclerosis - Updates and practice points.
    Best Pract Res Clin Rheumatol. 2021 Apr 22:101688. doi: 10.1016/j.berh.2021.101688

ABRIL 2021
  • Foeldvari I, Torok KS.
    Review for best practice in clinical rheumatology juvenile systemic sclerosis - Updates and practice points.
    Best Pract Res Clin Rheumatol. 2021 Apr 22:101688. doi: 10.1016/j.berh.2021.101688

  • Weibel L.
    Diagnosis and management of morphoea in children: an overview.
    Clin Exp Dermatol. 2021 Apr;46(3):487-494. 

  • Acosta-Herrera M, Kerick M, Lopéz-Isac E, Assassi S, Beretta L, Simeón-Aznar CP, et al.
    Comprehensive analysis of the major histocompatibility complex in systemic sclerosis identifies differential HLA associations by clinical and serological subtypes.
    Ann Rheum Dis. 2021 Apr 1:annrheumdis-2021-219884. doi: 10.1136/annrheumdis-2021-219884. Online ahead of print.

MARZO 2021
  • Foeldvari I, Klotsche J, Kasapcopur O, Adrovic A, Terreri MT, Sakamoto AP, et al.
    Differences sustained between diffuse and limited forms of juvenile systemic sclerosis in expanded international cohort. www.juvenile-scleroderma.com.
    Arthritis Care Res (Hoboken). 2021 Mar 30. doi: 10.1002/acr.24609. Online ahead of print.

  • Knights H, Minas E, Khan F, Shaw L, Al Obaidi M, Mankad K, Eleftheriou D.
    Magnetic resonance imaging findings in children with Parry-Romberg syndrome and en coup de sabre.
    Pediatr Rheumatol Online J. 2021 Mar 23;19(1):42.

  • Cerejeira D, Bonito F, António AM, Cunha H.
    Segmental stiff skin syndrome (SSS): Clinical case and a brief review.
    Australas J Dermatol. 2021 Mar 26. doi: 10.1111/ajd.13589. Online ahead of print.

  • Aringer M, Riemekasten G.
    Relevance of immunomodulatory therapy for interstitial lung disease in systemic sclerosis.
    Best Pract Res Clin Rheumatol. 2021 Mar 18:101672. doi: 10.1016/j.berh.2021.101672. Online ahead of print.

  • Gigante A, Hoffmann-Vold AM, Fegatelli DA, Gabrielli A, Leodori G, Coleiro B, De Santis M, et al.
    Estimated glomerular filtration rate is a marker of mortality in the European Scleroderma Trials and Research Group (EUSTAR) database.
    Rheumatology (Oxford). 2021 Mar 26:keab302. doi: 10.1093/rheumatology/keab302. Online ahead of print.

  • Young A, Moles VM, Jaafar S, Visovatti S, Huang S, Vummidi D, Nagaraja V, McLaughlin V, Khanna D.
    Performance of the DETECT Algorithm for Pulmonary Hypertension Screening in a Systemic Sclerosis Cohort.
    Arthritis Rheumatol. 2021 Mar 24. doi: 10.1002/art.41732. Online ahead of print.

ENERO 2021
  • Adrovic A, Yildiz M, Haslak F, Koker O, Aliyeva A, Sahin S, Barut K, Kasapcopur O.
    Tocilizumab therapy in juvenile systemic sclerosis: a retrospective single centre pilot study.
    Rheumatol Int. 2021 Jan;41(1):121-128. doi: 10.1007/s00296-020-04732-z. Epub 2020 Oct 27. PMID: 33108799.

  • Zulian F, Dal Pozzolo R, Meneghel A, Castaldi B, Marcolongo R, Caforio ALP, Martini G.
    Rituximab for rapidly progressive juvenile systemic sclerosis.
    Rheumatology (Oxford). 2020 Dec 1;59(12):3793-3797

  • Norikawa N, Kumekawa M, Yamamoto T.
    Juvenile temporal arteritis with eosinophilia associated with limited systemic sclerosis.
    Int J Dermatol. 2020 Dec;59(12):e475-e476

  • VFoeldvari I, Culpo R, Sperotto F, Anton J, Avcin T, Baildam E, Boros C, Chaitow J, Constantin T, Kasapcopur O, Knupp Feitosa de Oliveira S, Pilkington C, Toplak N, van Royen A, Saad Magalhaes C, Vastert SJ, Wulffraat N, Zulian F.
    Consensus-based recommendations for the management of juvenile systemic sclerosis.
    Rheumatology (Oxford). 2020 Nov 4. doi: 10.1093/rheumatology/keaa584.

  • Foeldvari I, Klotsche J, Hinrichs B, Helmus N, Kasapcopur O, Adrovic A, Sztajnbok F, Terreri MT, Anton J, Smith V, Katsicas M, Kostik M, Vasquez-Canizares N, Avcin T, Feldman B, Janarthanan M, Santos MJ, Sawhney S, Schonenberg-Meinema D, Sifuentes-Giraldo WA, Alexeeva E, Appenzeller S, Battagliotti C, Berntson L, Bica B, Costa Reis P, Eleftheriou D, Kallinich T, Lehman T, Marrani E, Minden K, Nielsen S, Nuruzzaman F, Patwardhan A, Khubchandani R, Stanevicha V, Uziel Y, Torok KS.
    Under detection of interstitial lung disease in juvenile systemic sclerosis (jSSc).
    Arthritis Care Res (Hoboken). 2020 Nov 3. doi: 10.1002/acr.24499
  • Virdi A, Patrizi A, Cambiaghi S, Diociaiuti A, El Hachem M, Schena D, Bassi A, Bonamonte D, Brazzelli V, Belloni Fortina A, Pepe P, Di Lernia V, Neri I.
    A retrospective study on clinical subtypes and management of morphea in 10 Italian Dermatological Units.
    G Ital Dermatol Venereol. 2020 Oct 16. doi: 10.23736/S0392-0488.20.06632-8. Online ahead of print.

  • Martini G, Saggioro L, Culpo R, Vittadello F, Meneghel A, Zulian F.
    Mycophenolate mofetil for methotrexate-resistant juvenile localized scleroderma.
    Rheumatology (Oxford). 2020 Sep 25:keaa392. doi: 10.1093/rheumatology/keaa392. Online ahead of print.

  • Allanore Y, Wung P, Soubrane C, Esperet C, Marrache F, Bejuit R, Lahmar A, Khanna D, Denton CP; Investigators.
    A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosis
    Ann Rheum Dis. 2020 Sep 22:annrheumdis-2020-218447. doi: 10.1136/annrheumdis-2020-218447. Online ahead of print.

  • Fan Y, Bender S, Shi W, Zoz D.
    Incidence and prevalence of systemic sclerosis and systemic sclerosis with interstitial lung disease in the United States.
    J Manag Care Spec Pharm. 2020 Sep 30:1-9. doi: 10.18553/jmcp.2020.20136. Online ahead of print.

  • Riccardi A, Marcoccia A, Borgia A, Guastafierro T, Bondanini F, Fasano S, Irace R, Messiniti V, Sanduzzi A, Bocchino M, Ciani A, D'Alto M, Argiento P, De Matteis GM, Spanò A, Valentini G.
    Undifferentiated connective tissue disease at risk of systemic sclerosis: A weighted score to identify patients who will evolve.
    Autoimmun Rev. 2019 Sep;18(9):102358. doi: 10.1016/j.autrev.2019.102358.

  • Hoffmann-Vold AM, Allanore Y, Alves M, Brunborg C, Airó P, Ananieva LP, Czirják L, Guiducci S, Hachulla E, Li M, Mihai C, Riemekasten G, Sfikakis PP, Kowal-Bielecka O, Riccardi A, Distler O.
    Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database.
    Ann Rheum Dis. 2020 Sep 28:annrheumdis-2020-217455. doi: 10.1136/annrheumdis-2020-217455. Online ahead of print.

  • Ciaffi J, van Leeuwen NM, Boonstra M, Kroft LJM, Schouffoer AA, Ninaber MK, Huizinga TWJ, de Vries-Bouwstra JK.
    Evolution of interstitial lung disease one year after hematopoietic stem cell transplantation or cyclophosphamide for systemic sclerosis.
    Arthritis Care Res (Hoboken). 2020 Sep 22. doi: 10.1002/acr.24451. Online ahead of print.

  • Denton CP, Laird B, Moros L, Luna Flores JL.
    Things left unsaid: important topics that are not discussed between patients with systemic sclerosis, their carers and their healthcare professionals-a discourse analysis.
    Clin Rheumatol. 2020 Sep 11. doi: 10.1007/s10067-020-05371-2. Online ahead of print.

  • Fallet B, Walker UA.
    Current immunosuppressive and antifibrotic therapies of systemic sclerosis and emerging therapeutic strategies.
    Expert Rev Clin Pharmacol. 2020 Oct 2. doi: 10.1080/17512433.2020.1832466.

  • Yin H, Li R, Lu L, Yan Q.
    Understanding Fibrosis in Systemic Sclerosis: Novel and Emerging Treatment Approaches.
    Curr Rheumatol Rep. 2020 Sep 21;22(11):77. doi: 10.1007/s11926-020-00953-0.

  • Jensen B, James R, Hong Y, Omoyinmi E, Pilkington C, Sebire NJ, Howell KJ, Brogan PA, Eleftheriou D.
    A case of Myhre syndrome mimicking juvenile scleroderma
    Pediatr Rheumatol Online J. 2020 Sep 11;18(1):72. doi: 10.1186/s12969-020-00466-1
    https: //pubmed.ncbi.nlm.nih.gov/32917212/

  • Kaushik, A, Mahajan R, De, Handa S.
    Paediatric morphoea: a holistic review. Part 1: epidemiology, aetiopathogenesis and clinical classification.
    Clin Exp Dermatol. 2020 Aug;45(6):673-678. doi: 10.1111/ced.14234. Epub 2020 May 30

  • Kaushik, A, Mahajan R, De, Handa S.
    Paediatric morphoea: a holistic review. Part 2: diagnosis, measures of disease activity, management and natural history
    Clin Exp Dermatol. 2020 Aug;45(6):679-684. doi: 10.1111/ced.14236.

  • Dag A, Tarakci E, Adrovic A, Kasapcopur O.
    Effects of Sense and Functionality Changes in the Hands on Activity and Participation in Patients with Juvenile Scleroderma.
    Mod Rheumatol.2020 Aug 28;1-25. doi: 10.1080/14397595.2020.1816612.
 JUNIO 2020
  • Francesco Zulian, Francesca Tirelli
    Treatment in Juvenile Scleroderma
    Curr Rheumatol Rep. 2020 Jun 26;22(8):45.  doi: 10.1007/s11926-020-00910-x.

  • Plachouri KM, Gkentzi D, Ravazoula P, Melachrinou M, Georgiou S.
    Pediatrician's Alert: Misdiagnosis of Mixed Localized Scleroderma in a Child.
    Pediatr Int. 2020 Jun;62(6):759-761. doi: 10.1111/ped.14170.

  • Civieri G, Castaldi B, Martini G, Meneghel A, Milanesi O, Zulian F.
    Early detection of ventricular dysfunction in juvenile systemic sclerosis by speckle tracking echocardiography.
    Rheumatology (Oxford). 2020 Jun 23:keaa208. doi: 10.1093/rheumatology/keaa208.

 MAYO 2020
  • Fadanelli G, Agazzi A, Vittadello F, Meneghel A, Zulian F, Martini G.
    Methotrexate in Linear Scleroderma: long-term efficacy in 50 children from a single Pediatric Rheumatology Centre.
    Arthritis Care Res (Hoboken). 2020 May 20.
  • Zloof Y, Schonfeld T, Dagan T, Amarilyo G, Braun M, Hashkes P, Harel L.
    Systemic Sclerosis Sine Scleroderma With Pulmonary Arterial Hypertension in a 3-Year-Old Girl.
    Pediatrics. 2020 May;145(5):e20192504.
  • Zulian F, Dal Pozzolo R, Meneghel A, Castaldi B, Marcolongo R, Caforio ALP, Martini G.
    Rituximab for rapidly progressive juvenile systemic sclerosis.
    Rheumatology (Oxford). 2020 May 23:keaa193.
  • Abbas LF, O'Brien JC, Goldman S, Pezeshk P, Chalian M, Chhabra A, Jacobe HT.
    A Cross-sectional Comparison of Magnetic Resonance Imaging Findings and Clinical Assessment in Patients With Morphea.
    JAMA Dermatol. 2020 Apr 1:e200036. doi: 10.1001/jamadermatol.2020.0036. Online ahead of print.
  • O'Brien JC, Nymeyer H, Green A, Jacobe HT.
    Changes in Disease Activity and Damage Over Time in Patients With Morphea.
    JAMA Dermatol. 2020 Apr 1:e200034. doi: 10.1001/jamadermatol.2020.0034. Online ahead of print.
  • Arthur M, Fett NM, Latour E, Jacobe H, Kunzler E, Florez-Pollack S, Houser J, Sharma S, Prasad S, Femia A, Stern MJ, Pappas-Taffer LK, Gaffney R, Fernandez AP, Knabel D, Cardones AR, Leung N, Laumann A, Yu JM, Zhao J, Vleugels RA, Tkachenko E, Lo K.
    Evaluation of the Effectiveness and Tolerability of Mycophenolate Mofetil and Mycophenolic Acid for the Treatment of Morphea.
    JAMA Dermatol. 2020 Apr 1:e200035. doi: 10.1001/jamadermatol.2020.0035. Online ahead of print.
MARZO 2020
  • Rubio-Rivas M, Corbella X, Guillén-Del-Castillo A, Tolosa Vilella C, Colunga Argüelles D, Argibay A et al. for the RESCLE investigators, Autoimmune Diseases Study Group (GEAS)
    Spanish scleroderma risk score (RESCLESCORE) to predict 15-year all-cause mortality in scleroderma patients at the time of diagnosis based on the RESCLE cohort: Derivation and internal validation.
    Autoimmun Rev. 2020 Mar 17:102507. doi: 10.1016/j.autrev.2020.102507. [Epub ahead of print]https://www.ncbi.nlm.nih.gov/pubmed/32194200
  • Enevoldsen FC, Sahana J, Wehland M, Grimm D, Infanger M, Krüger M.
    Endothelin Receptor Antagonists: Status Quo and Future Perspectives for Targeted Therapy.
    J Clin Med. 2020 Mar 18;9(3). pii: E824. doi: 10.3390/jcm9030824. 
  • Tang R, Yu J, Shi Y, Zou P, Zeng Z, Tang B, Wang Y, Ling G, Luo M, Xiao R.
    Safety and efficacy of Rituximab in systemic sclerosis: A systematic review and meta-analysis.
    Int Immunopharmacol. 2020 Mar 11;83:106389. doi: 10.1016/j.intimp.2020.106389. [Epub ahead of print]https://www.ncbi.nlm.nih.gov/pubmed/32172205
  • Chung MP, Chung L.
    Drugs in phase I and phase II clinical trials for systemic sclerosis.
    Expert Opin Investig Drugs. 2020 Mar 25:1-14. doi: 10.1080/13543784.2020.1743973. [Epub ahead of print]https://www.ncbi.nlm.nih.gov/pubmed/32178544
  • Flores Quispe SKJ, Cavaliere A, Weber M, Stramare R, Zuliani M, Quaia E, Zulian F, Giraudo C.
    Sarcopenia in juvenile localized scleroderma: new insights on deep involvement.
    Eur Radiol. 2020 Mar 6. doi: 10.1007/s00330-020-06764-2. [Epub ahead of print]https://www.ncbi.nlm.nih.gov/pubmed/32144460
  • Mecoli CA, Shah AA, Boin F, Wigley FM, Hummers LK.
    The Utility of Plasma Vascular Biomarkers in Systemic Sclerosis: A Prospective Longitudinal Analysis.
    Arthritis Rheumatol. 2020 Mar 21. doi: 10.1002/art.41265. [Epub ahead of print]https://www.ncbi.nlm.nih.gov/pubmed/32200572
  • Bellando-Randone S, Matucci-Cerinic M.
    The race against time to disclose lung inflammation in interstitial lung disease In systemic sclerosis: is PET scan the winning solution?
    Rheumatology (Oxford). 2020 Mar 11. pii: keaa077. doi: 10.1093/rheumatology/keaa077. [Epub ahead of print]
  • Ufuk F, Demirci M, Altinisik G.
    Quantitative computed tomography assessment for systemic sclerosis-related interstitial lung disease: comparison of different methods.
    Eur Radiol. 2020 Mar 19. doi: 10.1007/s00330-020-06772-2. [Epub ahead of print]https://www.ncbi.nlm.nih.gov/pubmed/32193641
  • Orteu CH, Ong VH, Denton CP.
    Scleroderma mimics - Clinical features and management.
    Best Pract Res Clin Rheumatol. 2020 Mar 5:101489. doi: 10.1016/j.berh.2020.101489. [Epub ahead of print]https://www.ncbi.nlm.nih.gov/pubmed/32147386
  • Cheema TJ, Young M, Rabold E, Barbieri AN, Baldwin N, Steen VD.
    Patient and Physician Perspectives on Systemic Sclerosis-Associated Interstitial Lung Disease.
    Clin Med Insights Circ Respir Pulm Med. 2020 Mar 18;14:1179548420913281.
  • Chung MP, Dontsi M, Postlethwaite D, Kesh S, Simard JF, Fiorentino D, Zaba LC, Chung L.
    Increased Mortality in Asians With Systemic Sclerosis in Northern California.
    ACR Open Rheumatol. 2020 Mar 21. doi: 10.1002/acr2.11126. [Epub ahead of print]https://www.ncbi.nlm.nih.gov/pubmed/32198914
  • Biney I, Dudney T, Goldman M, Carder L, Schriver E.
    Successful Use of Hyperbaric Oxygen as Adjunctive Therapy for a Nonhealing Venous Ulcer in a Patient with Systemic Sclerosis and Pulmonary Arterial Hypertension: A Case Report and Review of the Literature.
    Case Rep Pulmonol. 2020 Feb 24;2020:4750375. doi: 10.1155/2020/4750375.
  • Weibel L, Theiler M, Howell KJ, Denton CP, Waelchli R, Atherton D, Woo P, Harper JI.
    Prospective evaluation of treatment response and disease reversibility of paediatric localized scleroderma (morphoea) to steroids and methotrexate using multi-modal imaging.
    J Eur Acad Dermatol Venereol. 2020 Feb 20. doi: 10.1111/jdv.16308.
  • Li SC, Zheng RJ.
    Overview of Juvenile localized scleroderma and its management.
    World J Pediatr. 2020 Feb;16(1):5-18. doi: 10.1007/s12519-019-00320-9. Epub 2019 Nov 30.
  • Wu EY, Li SC, Torok KS, Virkud YV, Fuhlbrigge RC, Rabinovich CE; Childhood Arthritis and Rheumatology Research Alliance (CARRA) Legacy Registry Investigators.
    Baseline Description of the Juvenile Localized Scleroderma Subgroup From the Childhood Arthritis and Rheumatology Research Alliance Legacy Registry.
    ACR Open Rheumatol. 2019 Apr 10;1(2):119-124. doi: 10.1002/acr2.1019.
ENERO 2020
  • Do N, Ringold S, Sullivan E, Brandling-Bennett H.
    A retrospective study: Impact of consensus treatment plans on systemic therapy of pediatric morphea.
    Pediatr Dermatol. 2020 Jan 22. doi: 10.1111/pde.14074. [Epub ahead of print] https://www.ncbi.nlm.nih.gov/pubmed/31967352
  • Li SC, Torok KS, Rabinovich CE, Dedeoglu F, Becker ML, Ferguson PJ et al; CARRA Registry Investigators
    Initial Results from a Pilot Comparative Effectiveness Study of Three Methotrexate-Based Consensus Treatment Plans for Juvenile Localized Scleroderma
    J Rheumatol. 2019 Oct 15. pii: jrheum.190311. doi: 10.3899/jrheum.190311. [Epub ahead of print]
  • Foeldvari I.
    Update on the Systemic Treatment of Pediatric Localized Scleroderma
    Paediatr Drugs. 2019 Oct 31. doi: 10.1007/s40272-019-00363-5. [Epub ahead of print] Review.
  • Hoa S, Bernatsky S, Steele RJ, Baron M, Hudson M.
    Association between immunosuppressive therapy and course of mild interstitial lung disease in systemic sclerosis.
    Rheumatology (Oxford). 2019 Sep 19. pii: kez407. doi: 10.1093/rheumatology/kez407. [Epub ahead of print]https://www.ncbi.nlm.nih.gov/pubmed/31535689
  • Zigler CK, Ardalan K, Lane S, Schollaert KL, Torok KS.
    A novel patient-reported outcome for paediatric localized scleroderma: A qualitative assessment of content validity.
    Br J Dermatol. 2019 Sep 9. doi: 10.1111/bjd.18512. [Epub ahead of print]https://www.ncbi.nlm.nih.gov/pubmed/31498874
  • Barrat FJ, Lu TT.
    Role of type I interferons and innate immunity in systemic sclerosis: unbalanced activities on distinct cell types?
    Curr Opin Rheumatol. 2019 Aug 20. doi: 10.1097/BOR.0000000000000659.
  • Barrat FJ, Lu TT.
    Role of type I interferons and innate immunity in systemic sclerosis: unbalanced activities on distinct cell types?
    Curr Opin Rheumatol. 2019 Aug 20. doi: 10.1097/BOR.0000000000000659.
JULIO 2019
  •  Li SC, Fuhlbrigge RC, Laxer RM, Pope E, Ibarra MF, Stewart K, et al.Developing comparative effectiveness studies for a rare, understudied pediatric disease: lessons learned from the CARRA juvenile localized scleroderma consensus treatment plan pilot study.
    Pediatr Rheumatol Online J. 2019 Jul 15;17(1):43.
  • Elhai M, Boubaya M, Distler O, Smith V, Matucci-Cerinic M, Alegre Sancho JJ et al.
    Outcomes of patients with systemic sclerosis treated with Rituximab in contemporary practice: a prospective cohort study.
    Ann Rheum Dis. 2019 Jul;78(7):979-987.
  • Khanna D, Spino C, Johnson S, Chung L, Whitfield M, Denton CP et al.
    Abatacept in Early Diffuse Cutaneous Systemic Sclerosis - Results of a Phase 2 Investigator-Initiated, Multicenter, Double-Blind Randomized Placebo-Controlled Trial.
    Arthritis Rheumatol. 2019 Jul 24. doi: 10.1002/art.41055. [Epub ahead of print]
  • Gordon SM, Hughes JB, Nee R, Stitt RS, Bailey WT, Little DJ, Edison JD, Olson SW.
    Systemic sclerosis medications and risk of scleroderma renal crisis.
    BMC Nephrol. 2019 Jul 25;20(1):279.
  • Albuquerque JV, Andriolo BN, Vasconcellos MR, Civile VT, Lyddiatt A, Trevisani VF.
    Interventions for morphea.
    Cochrane Database Syst Rev. 2019 Jul 16;7:CD005027. doi: 10.1002/14651858.CD005027.pub5. [Epub ahead of print]

  • Sattar B, Chokshi RV.
    Colonic and Anorectal Manifestations of Systemic Sclerosis.
    Curr Gastroenterol Rep. 2019 Jul 8;21(7):33.
JUNIO 2019
  • Becker M, Graf N, Sauter R, Allanore Y, Curram J, Denton CP et al.
    Predictors of disease worsening defined by progression of organ damage in diffuse systemic sclerosis: a European Scleroderma Trials and Research (EUSTAR) analysis.
    Ann Rheum Dis. 2019 Jun 21. pii: annrheumdis-2019-215145. doi: 10.1136/annrheumdis-2019-215145. [Epub ahead of print] https://www.ncbi.nlm.nih.gov/pubmed/31227488
ABRIL 2019
  • Mertens JS, de Jong EMGJ, van den Hoogen LL, Wienke J, Thurlings RM, Seyger MMB, Hoppenreijs EPAH, Wijngaarde CA, van Vlijmen-Willems IMJJ, van den Bogaard E, Giovannone B, van Wijk F, van Royen-Kerkhof A, Marut W, Radstake TRD.
    The identification of CCL18 as biomarker of disease activity in localized scleroderma
    J Autoimmun. 2019 Apr 18. pii: S0896-8411(19)30091-5. doi: 10.1016/j.jaut.2019.04.008. [Epub ahead of print]
  • Kunzler E, Florez-Pollack S, Teske N, O'Brien J, Prasad S, Jacobe H.
    Linear morphea: Clinical characteristics, disease course, and treatment of the Morphea in Adults and Children cohort.
    J Am Acad Dermatol. 2019 Apr 17. pii: S0190-9622(19)30157-4. doi: 10.1016/j.jaad.2019.01.050. [Epub ahead of print]
  • Hennocq Q, Facchini A, Kverneland B, Bodemer C, Picard A, Khonsari RH.
    Craniofacial bone atrophy in Parry Romberg syndrome demonstrated using a Bayesian hierarchical model.
    J Craniomaxillofac Surg. 2019 Apr 8. pii: S1010-5182(18)31161-2. doi: 10.1016/j.jcms.2019.03.032. [Epub ahead of print]
MARZO 2019
  • Soh HJ, Samuel C, Heaton V, Renton WD, Cox A, Munro J.
    Challenges in the diagnosis and treatment of disabling pansclerotic morphea of childhood: case-based review.
    Rheumatol Int. 2019 Mar 5. doi: 10.1007/s00296-019-04269-w. [Epub ahead of print].

  • Ferdowsi N, Huq M, Stevens W, Hudson M, Wang M, Tay T, Burchell JL, Mancuso S, Rabusa C, Sundararajan V, Prior D, Proudman SM, Baron M, Nikpour M; Scleroderma Clinical Trials Consortium Damage Index Working Group, The Australian Scleroderma Interest Group, Canadian Scleroderma Research Group.
    Development and validation of the Scleroderma Clinical Trials Consortium Damage Index (SCTC-DI): a novel instrument to quantify organ damage in systemic sclerosis.
    Ann Rheum Dis. 2019 Mar 30. pii: annrheumdis-2018-214764. doi: 10.1136/annrheumdis-2018-214764. [Epub ahead of print]
  • Horimoto AMC, de Souza AS, Rodrigues SH, Kayser C.
    Risk of digital ulcers occurrence in systemic sclerosis: a cross-sectional study.
    Adv Rheumatol. 2019 Mar 28;59(1):14.
  • Skagen K, Hetlevik SO, Zamani M, Lilleby V, Skjelland M.
    Preclinical Carotid Atherosclerosis in Patients With Juvenile-Onset Mixed Connective Tissue Disease.
    J Stroke Cerebrovasc Dis. 2019 Feb 13. pii: S1052-3057(19)30036-9. doi: 10.1016/j.jstrokecerebrovasdis.2019.01.027.
ENERO 2019
  • Hetlevik SO, Flatø B, Aaløkken TM, Lund MB, Reiseter S, Mynarek GK, Nordal E, Rygg M, Lilleby V.
    Pulmonary Manifestations and Progression of Lung Disease in Juvenile-onset Mixed Connective Tissue Disease.
    J Rheumatol. 2019 Jan;46(1):93-100. doi: 10.3899/jrheum.180019. Epub 2018 Aug 1.
  • Lythgoe H, Almeida B, Bennett J, Bhat C, Bilkhu A, Brennan M, Deepak S, Dawson P, Eleftheriou D, Harrison K, Hawley D, Heaf E, Leone V, Long E, Maltby S, McErlane F, Rafiq N, Ramanan AV, Riley P, Rangaraj S, Varnier G, Wilkinson N, Pain CE.
    Multi-centre national audit of juvenile localised scleroderma: describing current UK practice in disease assessment and management.
    Pediatr Rheumatol Online J. 2018 Dec 18;16(1):80. doi: 10.1186/s12969-018-0295-0.
  • Li X, Qian YQ, Liu N, Mu R, Zuo Y, Wang GC, Jia Y, Li ZG
    Survival rate, causes of death, and risk factors in systemic sclerosis: a large cohort study.
    Clin Rheumatol. 2018 Nov;37(11):3051-3056. doi: 10.1007/s10067-018-4291-z.
  • Ambartsumyan L, Zheng HB, Iyer RS, Soares J, Henstorf G, Stevens AM.
    Relationship between esophageal abnormalities on fluoroscopic esophagram and pulmonary function testing in juvenile systemic sclerosis
    Arthritis Care Res (Hoboken). 2018 Oct 8. doi: 10.1002/acr.23778. [Epub ahead of print]
  • Boozalis E, Shah AA, Wigley F, Kang S, Kwatra SG.
    Morphea and systemic sclerosis are associated with an increased risk of melanoma and non-melanoma skin cancer
    J Am Acad Dermatol. 2018 Oct 20. pii: S0190-9622(18)32755-5. doi: 10.1016/j.jaad.2018.10.022. [Epub ahead of print]
  • Kurzinski K, Zigler CK, Torok KS.
    Prediction of Disease Relapse in a Cohort of Juvenile Localized Scleroderma Patients
    Br J Dermatol. 2018 Oct 13. doi: 10.1111/bjd.17312. [Epub ahead of print]
  • Zanatta E, Polito P, Favaro M, Larosa M, Marson P, Cozzi F, Doria A.
    Therapy of scleroderma renal crisis: State of the art.
    Autoimmun Rev. 2018 Sep;17(9):882-889.
  • Ram Poudel D, George M, Dhital R, Karmacharya P, Sandorfi N, Derk CT.
    Mortality, length of stay and cost of hospitalization among patients with systemic sclerosis: results from the National Inpatient Sample.
    Rheumatology (Oxford). 2018 Sep 1;57(9):1611-1622.
  • Dougherty DH, Kwakkenbos L, Carrier ME, Salazar G, Assassi S, Baron M, Bartlett SJ, Furst DE, Gottesman K, van den Hoogen F, Malcarne VL, Mouthon L, Nielson WR, Poiraudeau S, Sauvé M, Boire G, Bruns A, Chung L, Denton C, Dunne JV, Fortin P, Frech T, Gill A, Gordon J, Herrick AL, Hinchcliff M, Hudson M, Johnson SR, Jones N, Kafaja S, Larché M, Manning J, Pope J, Spiera R, Steen V, Sutton E, Thorne C, Wilcox P, Thombs BD, Mayes MD; SPIN Investigators
    The Scleroderma Patient-Centered Intervention Network Cohort: baseline clinical features and comparison with other large scleroderma cohorts.
    Rheumatology (Oxford). 2018 Sep 1;57(9):1623-1631
JULIO 2018
  • Maloney E, Menashe SJ, Iyer RS, Ringold S, Chakraborty AK, Ishak GE.
    The central nervous system manifestations of localized craniofacial scleroderma: a study of 10 cases and literature review.
    Pediatr Radiol. 2018 Jul 3. doi: 10.1007/s00247-018-4177-x. [Epub ahead of print]
  • Kashem SW, Correll CK, Vehe RK, Hobday PM, Binstadt BA, Maguiness SM.
    Inflammatory arthritis in pediatric patients with morphea.
    J Am Acad Dermatol. 2018 Jul;79(1):47-51.e2. doi: 10.1016/j.jaad.2018.03.005. Epub 2018 Mar 10.
JUNIO 2018
  • Siddiqui F, Kumar M.
    A 13-year-old girl with a linear dark patch on her forehead: A case of scleroderma en coup de sabre in a child with skin of color presenting with a bruise-like appearance.
    JAAD Case Rep. 2018 Apr 30;4(5):418-420. doi: 10.1016/j.jdcr.2017.08.018. eCollection 2018 Jun
  • Agazzi A, Fadanelli G, Vittadello F, Zulian F, Martini G.
    Reliability of LoSCAT score for activity and tissue damage assessment in a large cohort of patients with Juvenile Localized Scleroderma.
    Pediatr Rheumatol Online J. 2018 Jun 18;16(1):37. doi: 10.1186/s12969-018-0254-9
MAYO 2018
  • Denton CP, Ong VH, Xu S, Chen-Harris H, Modrusan Z, Lafyatis R, Khanna D, Jahreis A, Siegel J, Sornasse T.
    Therapeutic interleukin-6 blockade reverses transforming growth factor-beta pathway activation in dermal fibroblasts: insights from the faSScinate clinical trial in systemic sclerosis.
    Ann Rheum Dis. 2018 May 31. pii: annrheumdis-2018-213031. doi: 10.1136/annrheumdis-2018-213031. [Epub ahead of print] https://www.ncbi.nlm.nih.gov/pubmed/29853453
  • Martini G, Fadanelli G, Agazzi A, Vittadello F, Meneghel A, Zulian F.
    Disease course and long-term outcome of juvenile localized scleroderma: Experience from a single pediatric rheumatology Centre and literature review.
    Autoimmun Rev. 2018 May 3. pii: S1568-9972(18)30113-7. doi: 10.1016/j.autrev.2018.02.004. [Epub ahead of print] Review.
  • Constantin T, Foeldvari I, Pain CE, Pálinkás A, Höger P, Moll M, Nemkova D, Weibel L, Laczkovszki M, Clements P, Torok KS.
    Development of minimum standards of care for juvenile localized scleroderma.
    Eur J Pediatr. 2018 May 4. doi: 10.1007/s00431-018-3144-8. [Epub ahead of print] Review.
ABRIL 2018
  • Adrovic A, Sahin S, Barut K, Kasapcopur O.
    JUVENILE SCLERODERMA-what has changed in the meantime?
    Curr Rheumatol Rev. 2018 Apr 22. doi: 10.2174/1573397114666180423105056. [Epub ahead of print]

MARZO 2018
  • Fernández-Codina A, Fernández-Fernández J, Fernández-Pantiga A; en nombre del grupo vii de trabajo de final de master en Manejo Clínico de Enfermedades Autoinmunes Sistémicas de la Sociedad Española de Medicina Interna.
    Utilización de Tocilizumab en la esclerosis sistémica: breve revisión de la literatura.
    Rev Clin Esp. 2018 Mar 27. pii: S0014-2565(18)30063-8. doi: 10.1016/j.rce.2018.02.011. [Epub ahead of print] 

  • Kashem SW, Correll CK, Vehe RK, Hobday PM, Binstadt BA, Maguiness SM.
    Inflammatory arthritis in pediatric patients with morphea.
    J Am Acad Dermatol. 2018 Mar 10. pii: S0190-9622(18)30365-7. doi: 10.1016/j.jaad.2018.03.005. [Epub ahead of print]
  • Saigusa R, Asano Y, Yamashita T, Takahashi T, Nakamura K, Miura S, Ichimura Y, Toyama T, Taniguchi T, Sumida H, Tamaki Z, Miyazaki M, Yoshizaki A, Sato S.
    Systemic sclerosis complicated with localized scleroderma-like lesions induced by Köbner phenomenon.
    J Dermatol Sci. 2018 Mar;89(3):282-289.
  • Stevens BE, Torok KS, Li SC, Hershey N, Curran M, Higgins GC, Moore KF, Rabinovich CE, Dodson S, Stevens AM; CARRA Registry Investigators; Childhood Arthritis Rheumatology Research Alliance Stanford CA.
    Arthritis Care Res (Hoboken). 2018 Feb 18. doi: 10.1002/acr.23547. [Epub ahead of print]
    Clinical characteristics and factors associated with disability and impaired quality of life in children with juvenile systemic sclerosis
  • Seibold JR, Wigley FM.
    Editorial: Clinical Trials in Raynaud's Phenomenon: A Spoonful of Sugar (Pill) Makes the Medicine Go Down (in Flames).
    Arthritis Rheumatol. 2017 Dec;69(12):2256-2258. doi: 10.1002/art.40307. Epub 2017 Nov 10.
  • Cossu M, van Bon L, Preti C, Rossato M, Beretta L, Radstake TRDJ.
    Earliest Phase of Systemic Sclerosis Typified by Increased Levels of Inflammatory Proteins in the Serum.
    Arthritis Rheumatol. 2017 Dec;69(12):2359-2369.
  • Denton CP, Hachulla É, Riemekasten G, Schwarting A, Frenoux JM, Frey A, Le Brun FO, Herrick AL; Raynaud Study Investigators.
    Efficacy and Safety of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis: A Randomized, Placebo-Controlled, Phase II Study.
    Arthritis Rheumatol. 2017 Dec;69(12):2370-2379.
  • Gordon JK, Martyanov V, Franks JM, Bernstein EJ, Szymonifka J, Magro C, Wildman HF, Wood TA, Whitfield ML, Spiera RF.
    Belimumab for the Treatment of Early Diffuse Systemic Sclerosis: Results of a Randomized, Double-Blind, Placebo-Controlled, Pilot Trial.
    Arthritis Rheumatol. 2017 Oct 26. doi: 10.1002/art.40358. [Epub ahead of print]
      • Merlin E, Breton S, Fraitag S, Stéphan JL, Wouters C, Bodemer C, Bader-Meunier B.
        Fibrous Arthropathy Associated With Morphea: A New Cause of Diffuse Acquired Joint Contractures.
        Pediatrics. 2017 Oct;140(4). pii: e20161899. doi: 10.1542/peds.2016-1899.
      • Johnson SR, Soowamber ML, Fransen J, Khanna D, Van Den Hoogen F, Baron M, et al.
        There is a need for new systemic sclerosis subset criteria. A content analytic approach.
        Scand J Rheumatol. 2017 Oct 9:1-9. doi: 10.1080/03009742.2017.1299793
      • Barsotti S, Bruni C, Orlandi M, Della Rossa A, Marasco E, Codullo V, Guiducci S.
        One year in review 2017: systemic sclerosis
        Clin Exp Rheumatol. 2017 Sep-Oct;35 Suppl 106(4):3-20. Epub 2017 Sep 29. Review.
      • Lythgoe H, Baildam E, Beresford MW, Cleary G, McCann LJ, Pain CE.
        Tocilizumab as a potential therapeutic option for children with severe, refractory juvenile localized scleroderma
        Rheumatology (Oxford). 2017 Oct 25. doi: 10.1093/rheumatology/kex382. [Epub ahead of print]
      • Martini G, Campus S, Bernd R, Boscarol G, Meneghel A, Zulian F.
        Tocilizumab in two children with pansclerotic morphoea: a hopeful therapy for refractory cases?
        Clin Exp Rheumatol. 2017 Sep 29. [Epub ahead of print]
      • Knobler R, Moinzadeh P, Hunzelmann N, Kreuter A, Cozzio A, Mouthon L, Cutolo M, Rongioletti F,et al.
        European Dermatology Forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: localized scleroderma, systemic sclerosis and overlap syndromes.
        J Eur Acad Dermatol Venereol. 2017 Sep;31(9):1401-1424.
      • Kumánovics G, Péntek M, Bae S, Opris D, Khanna D, Furst DE, Czirják L.
        Assessment of skin involvement in systemic sclerosis.
        Rheumatology (Oxford). 2017 Sep 1;56(suppl_5):v53-v66. doi: 10.1093/rheumatology/kex202
      • Mertens JS, Thurlings RM, Kievit W, Seyger MMB, Radstake TRD, de Jong EMGJ.
        Long-term outcome of eosinophilic fasciitis: A cross-sectional evaluation of 35 patients.
        J Am Acad Dermatol. 2017 Sep;77(3):512-517.e5. doi: 10.1016/j.jaad.2017.05.018.
      • Iniesta Arandia N, Simeón-Aznar CP, Guillén Del Castillo A, Colunga Argüelles D, Rubio-Rivas M, Trapiella Martínez L, et al.
        Influence of antibody profile in clinical features and prognosis in a cohort of Spanish patients with systemic sclerosis.
        Clin Exp Rheumatol. 2017 Sep 21. [Epub ahead of print]
      • Freire M, Rivera A, Sopeña B, Tolosa Vilella C, Guillén-Del Castillo A, Colunga Argüelles D, et al.
        Clinical and epidemiological differences between men and women with systemic sclerosis: a study in a Spanish systemic sclerosis cohort and literature review.
        Clin Exp Rheumatol. 2017 Sep 18. [Epub ahead of print] Review.
      • Dedeoglu R, Adroviç A, Oztunç F, Sahin S, Barut K, Kasapcopur O.
        New Insights into Cardiac Involvement in Juvenile Scleroderma: A Three-Dimensional Echocardiographic Assessment Unveils Subclinical Ventricle Dysfunction.
        Pediatr Cardiol. 2017 Sep 14. doi: 10.1007/s00246-017-1714-6. [Epub ahead of print]
      • Ardalan K, Zigler CK, Torok KS.
        Predictors of Longitudinal Quality of Life in Juvenile Localized Scleroderma.
        Arthritis Care Res (Hoboken). 2017 Jul;69(7):1082-1087. doi: 10.1002/acr.23101. Epub 2017 Jun 7.
JULIO 2017
      • Ardalan K, Zigler CK, Torok KS.
        Predictors of Longitudinal Quality of Life in Juvenile Localized Scleroderma.
        Arthritis Care Res (Hoboken). 2017 Jul;69(7):1082-1087. doi: 10.1002/acr.23101. Epub 2017 Jun 7.
JUNIO 2017
      • Li T, Liu Y, Xu H.
        Successful treatment of infliximab in a patient with scleroderma: a case report.
        Medicine (Baltimore). 2017 Jun;96(22):e6737.
      • Bissell LA, Md Yusof MY, Buch MH.
        Primary myocardial disease in scleroderma-a comprehensive review of the literature to inform the UK Systemic Sclerosis Study Group cardiac working group.
        Rheumatology (Oxford). 2017 Jun 1;56(6):882-895
      • Giacomelli R, Liakouli V, Berardicurti O, Ruscitti P, Di Benedetto P, Carubbi F, Guggino G, Di Bartolomeo S, Ciccia F, Triolo G, Cipriani P.
        Interstitial lung disease in systemic sclerosis: current and future treatment.
        Rheumatol Int. 2017 Jun;37(6):853-863.

      • Pellar RE, Pope JE.
        Evidence-based management of systemic sclerosis: Navigating recommendations and guidelines.
        Semin Arthritis Rheum. 2017 Jun;46(6):767-774
MAYO 2017
ABRIL 2017
MARZO 2017
      • Volkmann ER, Tashkin DP, Li N, Roth MD, Khanna D, Hoffmann-Vold AM, Kim G, Goldin J, Clements PJ, Furst DE, Elashoff RM.
        Mycophenolate versus Placebo for Systemic Sclerosis-Related Interstitial Lung Disease: An Analysis of Scleroderma Lung Studies I and II.
        Arthritis Rheumatol. 2017 Apr 4. doi: 10.1002/art.40114.
      • Boulos D, Ngian GS, Rajadurai A, Elford K, Stevens W, Proudman S, Owen C, Roddy J, Nikpour M, Youssef P, Hill C, Sahhar J.
        Long-term efficacy and tolerability of mycophenolate mofetil therapy in diffuse scleroderma skin disease.
        Int J Rheum Dis. 2017 Mar 24. doi: 10.1111/1756-185X.13035.
      • Nevskaya T, Baron M, Pope JE; Canadian Scleroderma Research Group.
        Predictive value of European Scleroderma Group Activity Index in an early scleroderma cohort.
        Rheumatology (Oxford). 2017 Mar 17. doi: 10.1093/rheumatology/kex015.
ENERO 2017
      • Eutsler EP, Horton DB, Epelman M, Finkel T, Averill LW.
        Musculoskeletal MRI findings of juvenile localized scleroderma.
        Pediatr Radiol. 2017 Jan 14. doi: 10.1007/s00247-016-3765-x. [Epub ahead of print]
      • Garcia-Romero MT, Randhawa HK, Laxer R, Pope E.
        The role of local temperature and other clinical characteristics of localized scleroderma as markers of disease activity.
        Int J Dermatol. 2017 Jan;56(1):63-67. doi: 10.1111/ijd.13452.
      • Hetlevik SO, Flatø B, Rygg M, Nordal EB, Brunborg C, Hetland H, Lilleby V.
        Long-term outcome in juvenile-onset mixed connective tissue disease: a nationwide Norwegian study.
        Ann Rheum Dis. 2017 Jan;76(1):159-165. doi: 10.1136/annrheumdis-2016-209522. Epub 2016 Jun 9.
      • Valentini G, Iudici M, Walker UA, Jaeger VK, Baron M, Carreira P, Czirják L, Denton CP, Distler O, Hachulla E, Herrick AL, Kowal-Bielecka O, Pope J, Müller-Ladner U, Riemekasten G, Avouac J, Frerix M, Jordan S, Minier T, Siegert E, Ong VH, Vettori S, Allanore Y.
        The European Scleroderma Trials and Research group (EUSTAR) task forcé for the development of revised activity criteria for systemic sclerosis: derivation and validation of a preliminarily revised EUSTAR activity index.
        Ann Rheum Dis. 2017 Jan;76(1):270-276.
      • Silva M, Ribeiro R, Oliveira J.
        Pseudoainhum in Systemic Sclerosis.
        J Rheumatol. 2016 Nov;43(11):2076.
      • Stevens AM, Kanaan SB, Torok KS, Medsger TA, Mayes MD, Reveille JD, Klein-Gitelman M, Reed AM, Lee T, Li SC, Henstorf G, Luu C, Aydelotte T, Lee Nelson J.
        HLA-DRB1, DQA1, and DQB1 in Juvenile-Onset Systemic Sclerosis.
        Arthritis Rheumatol. 2016 Nov;68(11):2772-2777.
      • Trombetta AC, Pizzorni C, Ruaro B, Paolino S, Sulli A, Smith V, Cutolo M.
        Effects of Longterm Treatment with Bosentan and Iloprost on Nailfold Absolute Capillary Number, Fingertip Blood Perfusion, and Clinical Status in Systemic Sclerosis.
        J Rheumatol. 2016 Nov;43(11):2033-2041.
      • Pain CE, Constantin T, Toplak N, Moll M, Iking-Konert C, Piotto DP, Aktay Ayaz N, Nemcova D, Hoeger PH, Cutolo M, Smith V, Foeldvari I; Paediatric Rheumatology European Society (PRES) Juvenile Scleroderma Working Group.
        Raynaud's syndrome in children: systematic review and development of recommendations for assessment and monitoring
        Clin Exp Rheumatol. 2016 Sep-Oct;34 Suppl 100(5):200-206.
      • Zulian F, Balzarin M, Birolo C.
        Recent advances in the management of juvenile systemic sclerosis
        Expert Rev Clin Immunol. 2016 Oct 3
      • Cabrera N, Duquesne A, Desjonquères M, Larbre JP, Lega JC, Fabien N, Belot A.
        Tocilizumab in the treatment of mixed connective tissue disease and overlap syndrome in children.
        RMD Open. 2016 Sep 15;2(2):e000271.
      • Valões CC, Novak GV, Brunelli JB, Kozu KT, Toma RK, Silva CA.
        Esophageal abnormalities in juvenile localized scleroderma: is it associated with other extracutaneous manifestations?
        Rev Bras Reumatol. 2016 Sep 17.
      • Woodworth TG, Suliman YA, Furst DE, Clements P.
        Scleroderma renal crisis and renal involvement in systemic sclerosis.
        Nat Rev Nephrol. 2016 Sep 19. doi: 10.1038/nrneph.2016.124. [Epub ahead of print].
      • Valentini G, Iudici M, Walker UA, Jaeger VK, Baron M, Carreira P, Czirják L, Denton CP, Distler O, Hachulla E, Herrick AL, Kowal-Bielecka O, Pope J, Müller-Ladner U, Riemekasten G, Avouac J, Frerix M, Jordan S, Minier T, Siegert E, Ong VH, Vettori S, Allanore Y.
        The European Scleroderma Trials and Research group (EUSTAR) task force for the development of revised activity criteria for systemic sclerosis: derivation and validation of a preliminarily revised EUSTAR activity index.
        Ann Rheum Dis. 2016 Sep 12. pii: annrheumdis-2016-209768. doi: 10.1136/annrheumdis-2016-209768. [Epub ahead of print]
      • Distler JH, Feghali-Bostwick C, Soare A, Asano Y, Distler O, Abraham DJ.
        Frontiers of antifibrotic therapy in systemic sclerosis.
        Arthritis Rheumatol. 2016 Sep 16. doi: 10.1002/art.39865. [Epub ahead of print]
      • Crowell MD, Umar SB, Griffing WL, DiBaise JK, Lacy BE, Vela MF.
        Esophageal Motor Abnormalities in Patients with Scleroderma: Heterogeneity, Risk Factors, and Effects on Quality of Life.
        Clin Gastroenterol Hepatol. 2016 Sep 6. pii: S1542-3565(16)30615-2. doi: 10.1016/j.cgh.2016.08.034. [Epub ahead of print]
      • Baron M, Pope J, Robinson D, Jones N, Khalidi N, Docherty P, Kaminska E, Masetto A, Sutton E, Mathieu JP, Ligier S, Grodzicky T, LeClercq S, Thorne C, Gyger G, Smith D, Fortin PR, Larché M, Abu-Hakima M, Rodriguez-Reyna TS, Cabral-Castaneda AR, Fritzler MJ, Wang M, Hudson M.
        Calcinosis is associated with digital ischaemia in systemic sclerosis-a longitudinal study.
        Rheumatology (Oxford). 2016 Sep 4. pii: kew313. [Epub ahead of print] http://www.ncbi.nlm.nih.gov/pubmed/27593964
      • Fotis L, Baszis KW, White AJ, French AR.
        Four Cases of Anti-PM/Scl Antibody-positive Juvenile Overlap Syndrome with Features of Myositis and Systemic Sclerosis.
        J Rheumatol. 2016 Sep;43(9):1768-9.
      • Sakkas LI.
        Spotlight on tocilizumab and its potential in the treatment of systemic sclerosis.
        Drug Des Devel Ther. 2016 Aug 29;10:2723-8.
      • Ando K, Nakashita T, Kaneko N, Takahashi K, Motojima S.
        Associations between peripheral blood eosinophil counts in patients with systemic sclerosis and disease severity.
        Springerplus. 2016 Aug 23;5(1):1401.
JUNIO 2016
      • Sanges S, Desauw C, de Groote P, Fertin M, Lamblin N, Bervar JF, Hatron PY, Hachulla E, Launay D.
        Tolerance of bevacizumab therapy in systemic sclerosis-associated pulmonary arterial hypertension: A case report.
        Rev Med Interne. 2016 Jun 28. pii: S0248-8663(16)30410-6. doi: 10.1016/j.revmed.2016.05.020
MAYO 2016
ABRIL 2016
MARZO 2016
      • Dobrota R, Maurer B, Graf N, Jordan S, Mihai C, Kowal-Bielecka O, Allanore Y, Distler O; EUSTAR coauthors.
        Prediction of improvement in skin fibrosis in diffuse cutaneous systemic sclerosis: a EUSTAR analysis.
        Ann Rheum Dis. 2016 Mar 25. pii: annrheumdis-2015-208024. doi: 10.1136/annrheumdis-2015-208024. [Epub ahead of print] http://www.ncbi.nlm.nih.gov/pubmed/27016052
      • Ligon C, Hummers LK.
        Biomarkers in Scleroderma: Progressing from Association to Clinical Utility.
        Curr Rheumatol Rep. 2016 Mar;18(3):17. doi: 10.1007/s11926-016-0565-0.
      • Gigante A, Barbano B, Barilaro G, Quarta S, Gasperini ML, Di Mario F, Romaniello A, Amoroso A, Cianci R, Rosato E.
        Serum uric acid as a marker of microvascular damage in systemic sclerosis patients.
        Microvasc Res. 2016 Mar 18. pii: S0026-2862(16)30021-8. doi: 10.1016/j.mvr.2016.03.007. [Epub ahead of print] http://www.ncbi.nlm.nih.gov/pubmed/27003713
      • Stella Aslibekyan, Vincent A. Laufer, Donna K. Arnett and S. Louis Bridges
        A novel genetic association with systemic sclerosis: The utility of whole exome sequencing in autoimmune disease
        Arthritis & Rheumatology. DOI: 10.1002/art.39451
      • Athanasios Mavropoulos, Theodora Simopoulou, Areti Varna, Christos Liaskos, Christina Katsiari, Dimitrios P. Bogdanos and Lazaros I. Sakkas
        B regulatory cells are decreased and functionally impaired in patients with systemic sclerosis

        Arthritis & Rheumatology DOI: 10.1002/art.39437
      • Alexandre TJ Maria, Karine Toupet, Claire Bony, Nelly Pirot, Marie-Catherine Vozenin, Benoît Petit, Pascal Roger, Frédéric Batteux, Alain Le Quellec, Christian Jorgensen, Danièle Noël and Philippe Guilpain
        Anti-fibrotic, anti-oxidant and immunomodulatory effects of mesenchymal stem cells in HOCl-induced systemic sclerosis

        Arthritis & Rheumatology. DOI: 10.1002/art.39477
      • Ramos, Paula S; Silver, Richard M; Feghali-Bostwick, Carol A
        Genetics of systemic sclerosis: recent advances

        Current Opinion in Rheumatology:
        November 2015 - Volume 27 - Issue 6 - p 521–529
        doi: 10.1097/BOR.0000000000000214
      • Lara Bossini-Castillo, , Elena López-Isac, Javier Martín
        Immunogenetics of systemic sclerosis: Defining heritability, functional variants and shared-autoimmunity pathways
        Journal of Autoimmunity
        Volume 64, November 2015, Pages 53–65
      • Hughes M, Ong VH, Anderson ME, Hall F, Moinzadeh P, Griffiths B, Baildam E, Denton CP, Herrick AL
        Consensus best practice pathway of the UK Scleroderma Study Group: digital vasculopathy in systemic sclerosis.
        Rheumatology (Oxford). 2015 Nov;54(11):2015-24. doi: 10.1093/rheumatology/kev201.
      • Simeón-Aznar CP, Fonollosa-Plá V, Tolosa-Vilella C, Espinosa-Garriga G, Campillo-Grau M, Ramos-Casals M, García-Hernández FJ, Castillo-Palma MJ, Sánchez-Román J, Callejas-Rubio JL, Ortego-Centeno N, Egurbide-Arberas MV, Trapiellla-Martínez L, Caminal-Montero L, Sáez-Comet L, Velilla-Marco J, Camps-García MT, de Ramón-Garrido E, Esteban-Marcos EM, Pallarés-Ferreres L, Navarrete-Navarrete N, Vargas-Hitos JA, Torre RG, Salvador-Cervello G, Rios-Blanco JJ, Vilardell-Tarrés M; Spanish Scleroderma Study Group (SSSG), Autoimmune Diseases Study Group (GEAS), Spanish Society of Internal Medicine (SEMI).
        Registry of the Spanish Network for Systemic Sclerosis: Survival, Prognostic Factors, and Causes of Death.
        Medicine (Baltimore). 2015 Oct;94(43):e1728.
      • Avouac J, Riemekasten G, Meune C, Ruiz B, Kahan A, Allanore Y.
        Autoantibodies against Endothelin 1 Type A Receptor Are Strong Predictors of Digital Ulcers in Systemic Sclerosis
        J Rheumatol October 2015;42(10):1801-7; doi:10.3899/jrheum.150061
      • Torok KS, Kurzinski K, Kelsey C, Yabes J, Magee K, Vallejo AN, Medsger T Jr, Feghali-Bostwick CA.
        Peripheral blood cytokine and chemokine profiles in juvenile localized scleroderma: T-helper cell-associated cytokine profiles.
        Semin Arthritis Rheum. 2015 Jun 17. pii:S0049-0172(15)00144-4.doi:10.1016/j.semarthrit.2015.06.006. EPUB ahead of print]
      • Poff S, Li SC, Kelsey CE, Foeldvari I, Torok KS.
        Durometry as an Outcome Measure in Juvenile Localized Scleroderma.
        Br J Dermatol. 2015 Aug 24. doi:10.1111/bjd.14103. EPUB ahead of print]
      • Ingegnoli F, Boracchi P, Gualtierotti R, Smith V, Cutolo M, Foeldvari I; EUSTAR co-authors.
        A comparison between nailfold capillaroscopy patterns in adulthood in juvenile and adult-onset systemic sclerosis: A EUSTAR exploratory study.
        Microvasc Res. 2015 Aug 4;102:19-24. doi:10.1016/j.mvr.2015.07.007. EPUB ahead of print] http://www.ncbi.nlm.nih.gov/pubmed/26254260
JUNIO 2015
      • Hughes M, Ong VH, Anderson ME, Hall F, Moinzadeh P, Griffiths B, Baildam E, Denton CP, Herrick AL.
        Consensus best practice pathway of the UK Systemic Sclerosis Study Group: digital vasculopathy in systemic sclerosis.
        Rheumatology (Oxford). 2015 Jun 26. pii: kev201. [Epub ahead of print] http://www.ncbi.nlm.nih.gov/pubmed/26116156
MAYO 2015
      • Eric Hachulla, Pierre-Yves Hatron, Patrick Carpentier, Christian Agard, Emmanuel Chatelus, Patrick Jego, et al, on behalf of the SEDUCE study group.
        Efficacy of sildenafil on ischaemic digital ulcer healing in systemic sclerosis: the placebo-controlled SEDUCE study.
        Ann Rheum Dis doi:10.1136/annrheumdis-2014-207001 [Published on line: 20 may 2015] http://ard.bmj.com/content/early/2015/05/20/annrheumdis-2014-207001.abstract
      • Britta Maurer, Nicole Graf, Beat A Michel, Ulf Müller-Ladner, László Czirják, Christopher P Denton, et al, EUSTAR co-authors
        Extended report: Prediction of worsening of skin fibrosis in patients with diffuse cutaneous systemic sclerosis using the EUSTAR database
        Ann Rheum Dis 2015;74:1124-1131 doi:10.1136/annrheumdis-2014-205226
      • Suzana Jordan, Jörg H W Distler, Britta Maurer, Dörte Huscher, Jacob M van Laar, Yannick Allanore, et al on behalf of the EUSTAR Rituximab study group
        Extended report: Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group.
        Ann Rheum Dis 2015;74:1188-1194 doi:10.1136/annrheumdis-2013-204522
      • Young, Amber; Khanna, Dinesh
        Systemic sclerosis: a systematic review on therapeutic management from 2011 to 2014
        Current Opinion in Rheumatology, May 2015, Vol 27, Issue 3
      • Fiona M. McQueen and Kamal Solanki
        Rituximab in diffuse cutaneous systemic sclerosis: should we be using it today?
        Rheumatology (2015) 54 (5): 757-767 doi:10.1093/rheumatology/keu463
ABRIL 2015
MARZO 2015
        • Mertens JS, Seyger MM, Kievit W, Hoppenreijs EP, Jansen TL, van de Kerkhof PC, Radstake TR, de Jong EM.
          Disease recurrence in localized scleroderma: a retrospective analysis of 344 patients with paediatric- or adult-onset disease.
          Br J Dermatol. 2015 Mar;172(3):722-8. doi: 10.1111/bjd.13514
        • Young A, Khanna D.
          Systemic sclerosis: a systematic review on therapeutic management from 2011 to 2014.
          Curr Opin Rheumatol. 2015 May;27(3):241-8. doi: 10.1097/BOR
        • Moinzadeh P, Aberer E, Ahmadi-Simab K, Blank N, Distler JHW, Fierlbeck G et al
          Disease progression in systemic sclerosis-overlap syndrome is significantly different from limited and diffuse cutaneous systemic sclerosis
          Ann Rheum Dis 2015;74:730-737. doi:10.1136/annrheumdis-2013-204487
        • Wu CY, Asano Y, Taniguchi T, Sato S, Yu HS.
          Serum heparanase levels: A protective marker against digital ulcers in patients with systemic sclerosis.
          J Dermatol. 2015 Mar 21. doi: 10.1111/1346-8138.12842. [Epub ahead of print]
        • Foeldvari I.
          Update on juvenile systemic sclerosis
          Curr Rheumatol Rep. 2015 Mar;17(3):491. doi: 10.1007/s11926-014-0491-y.
        • Hughes M, Snapir A, Wilkinson J, Snapir D, Wigley FM, Herrick AL.
          Prediction and impact of attacks of Raynaud's phenomenon, as judged by patient perception.
          Rheumatology (Oxford). 2015 Mar 9. pii: kev002. [Epub ahead of print]
        • Hughes M, Moore T, O'Leary N, Tracey A, Ennis H, Dinsdale G, Murray A, Roberts C, Herrick AL.
          A study comparing videocapillaroscopy and dermoscopy in the assessment of nailfold capillaries in patients with systemic sclerosis-spectrum disorders.
          Rheumatology (Oxford). 2015 Mar 6. pii: keu533. [Epub ahead of print]http://www.ncbi.nlm.nih.gov/pubmed/25749623
      • Gerhold K, Becker MO.
        Nailfold capillaroscopy in juvenile rheumatic diseases: known measures, patterns and indications.
        Clin Exp Rheumatol. 2014 Nov-Dec;32(6 Suppl 86):S-183-8.
      • Falcini F, Rigante D, Candelli M, Martini G, Corona F, Petaccia A, La Torre F, Raffaele CG, Matucci Cerinic M.
        Anti-nuclear antibodies as predictor of outcome in a multi-center cohort of Italian children and adolescents with Raynaud's phenomenon.
        Clin Rheumatol. 2014 Nov 28. [Epub ahead of print]
      • Polcari I, Moon A, Mathes EF, Gilmore ES, Paller AS.
        Headaches as a Presenting Symptom of Linear Morphea en Coup de Sabre.
        Pediatrics. 2014 Nov 17. pii: peds.2014-0019. [Epub ahead of print]
      • Mertens JS, Seyger MM, Kievit W, Hoppenreijs EP, Jansen TL, van de Kerkhof PC, Radstake TR, de Jong EM.
        Disease recurrence in localized scleroderma: a retrospective analysis of 344 patients with pediatric or adult-onset disease.
        Br J Dermatol. 2014 Nov 7 [Epub ahead of print]
      • Condie D, Grabell D, Jacobe H.
        Comparison of outcomes in adults with pediatric-onset morphea and those with adult-onset morphea: a cross-sectional study from the morphea in adults and children cohort.
        Arthritis Rheumatol. 2014 Dec;66(12):3496-504.
      • Taniguchi T, Asano Y, Tamaki Z, Akamata K, Aozasa N, Noda S, Takahashi T, Ichimura Y, Toyama T, Sugita M, Sumida H, Kuwano Y, Miyazaki M, Yanaba K, Sato S.
        Histological features of localized scleroderma 'en coup de sabre': a study of 16 cases.
        J Eur Acad Dermatol Venereol. 2014 Dec;28(12):1805-10.
      • Jackson CT, Maibach HI.
        Localized scleroderma variants: pharmacologic implications.
        J Dermatolog Treat. 2014 Dec;25(6):529-31.
      • Hong BY1, Giang R, Mbuagbaw L, Larche M, Thabane L
        Factors associated with development of gastrointestinal problems in patients with scleroderma: a protocol for a systematic review.
        Syst Rev. 2014 Oct 13;3(1):115. doi: 10.1186/2046-4053-3-115.
      • Hoffmann-Vold AM, Gunnarsson R, Garen T, Midtvedt O, Molberg O.
        Performance of the 2013 American College of Rheumatology/European League Against Rheumatism Classification Criteria for Systemic Sclerosis (SSc) in Large, Well-defined Cohorts of SSc and Mixed Connective Tissue Disease.
        J Rheumatol. 2014 Oct 1. pii: jrheum.140047. [Epub ahead of print]http://www.ncbi.nlm.nih.gov/pubmed/25274890
  • Jacobe H, Ahn C, Arnett F, Reveille JD.
    Major histocompatibility complex (MHC) class I and II alleles which confer susceptibility or protection in the Morphea in Adults and Children (MAC) cohort.
    Arthritis Rheumatol. 2014 Sep 15. doi: 10.1002/art.38814. [Epub ahead of print]http://www.ncbi.nlm.nih.gov/pubmed/25223600
      • van Bon L1, Cossu M1, Loof A2, Gohar F3, Wittkowski H3, Vonk M4, Roth J5, van den Berg W4, van Heerde W2, Broen JC6, Radstake TR6.
        Proteomic analysis of plasma identifies the Toll-like receptor agonists S100A8/A9 as a novel possible marker forsystemic sclerosis phenotype.
        Ann Rheum Dis. 2014 Aug;73(8):1585-9. doi: 10.1136/annrheumdis-2013-205013. Epub 2014 Apr 9.
JULIO 2014
      • Launay D, Savale L, Berezne A, Le Pavec J, Hachulla E, Mouthon L, Sitbon O, Lambert B, Gaudric M, Jais X, Stephan F, Hatron PY, Lamblin N, Vignaux O, Cottin V, Farge D, Wallaert B, Guillevin L, Simonneau G, Mercier O, Fadel E, Dartevelle P, Humbert M, Mussot S; On behalf of the Working Group on Heart/Lung transplantation in systemic sclerosis of the French Network on Pulmonary Hypertension.
        Lung and heart-lung transplantation for systemic sclerosis patients. A monocentric experience of 13 patients, review of the literature and position paper of a multidisciplinary Working Group.
        Presse Med. 2014 Jul 11. pii: S0755-4982(14)00311-X. doi: 10.1016/j.lpm.2014.01.020.
      • Saad Magalhães C, Fernandes Tde A, Fernandes TD, Resende LA.
        A cross-sectional electromyography assessment in linear sclerodermapatients.
        Pediatr Rheumatol Online J. 2014 Jul 12;12:27.
JUNIO 2014
      • Schicchi N, Valeri G, Moroncini G, Agliata G, Salvolini L, Gabrielli A, Giovagnoni A.
        Myocardial perfusion defects in scleroderma detected by contrast-enhanced cardiovascular magnetic resonance.
        Radiol Med. 2014 Jun 7. [Epub ahead of print]http://www.ncbi.nlm.nih.gov/pubmed/24907065
      • Webber M, Natarajan A, Schreiber B, Sanjay P, Schwaiger J, Handler C, Coghlan G.
        136 Cardiac involvement in systemic sclerosis: strengths and limitations of cardiac magnetic resonance imaging.
        Heart. 2014 Jun;100 Suppl 3:A80. doi: 10.1136/heartjnl-2014-306118.136.
MAYO 2014
      • Yilmaz N, Can M, Kocakaya D, Karakurt S, Yavuz S.
        Two-year experience with mycophenolate mofetil in patients with scleroderma lung disease: a case series.
        Int J Rheum Dis. 2014 May 26. doi: 10.1111/1756-185X.12399. [Epub ahead of print]
      • Hawley DP1, Pain CE2, Baildam EM2, Murphy R2, Taylor AE2, Foster HE3.
        United Kingdom survey of current management of juvenile localized scleroderma.
        Rheumatology (Oxford). 2014 May 21. pii: keu212. [Epub ahead of print]
MARZO 2014
      • Hatta Y1, Hasegawa M, Matsushita T, Hamaguchi Y, Fujimoto M, Takehara K.
        The clinical characteristics of juvenile-onset systemic sclerosis in Japanese patients.
        Mod Rheumatol. 2014 Mar;24(2):377-9. doi: 10.3109/14397595.2013.854073.
ENERO 2014
      • Jordan S, Distler JH, Maurer B, Huscher D, van Laar JM, Allanore Y, Distler O; on behalf of the EUSTAR Rituximab study group.
        Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group.
        Ann Rheum Dis. 2014 Jan 17. doi: 10.1136/annrheumdis-2013-204522. [Epub ahead of print]http://www.ncbi.nlm.nih.gov/pubmed/24442885
      • Khanna D, Gladue H, Channick R et al.
        Recommendations for screening and detection of connective tissue disease-associated pulmonary arterial hypertension.
        Arthritis Rheum. 2013 Dec;65(12):3194-201. doi: 10.1002/art.38172
      • van den Hoogen F, Khanna D, Fransen J, Johnson SR et al.
        2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative.
        Arthritis Rheum. 2013 Nov;65(11):2737-47. doi: 10.1002/art.38098.
      • Gladue H, Steen V, Allanore Y, Saggar R, Saggar R, Maranian P, Berrocal VJ, Avouac J, Meune C, Trivedi M, Khanna D.
        Combination of Echocardiographic and Pulmonary Function Test Measures Improves Sensitivity for Diagnosis of Systemic Sclerosis-associated Pulmonary Arterial Hypertension: Analysis of 2 Cohorts.
        J Rheumatol. 2013 Aug 15. [Epub ahead of print]
ABRIL 2013
ENERO 2013
      • Bonifazi M, Tramacere I, Pomponio G, Gabrielli B, Avvedimento EV, La Vecchia C, Negri E, Gabrielli A.
        Systemic sclerosis (scleroderma) and cancer risk: systematic review and meta-analysis of observational studies.
        Rheumatology (Oxford) 2013 Jan;52(1):143-54. doi: 10.1093/rheumatology/kes303. Epub 2012 Nov 22.
      • Schanz S, Henes J, Ulmer A, Kötter I, Fierlbeck G, Claussen CD, Horger M.
        Magnetic resonance imaging findings in patients with systemic scleroderma and musculoskeletal symptoms.
        Eur Radiol 2013 Jan;23(1):212-21. doi: 10.1007/s00330-012-2584-1.
      • La Torre F, Giorgia Martini G, Russo R, Katsicas MM, Corona F, Calcagno G, Falcini F, Vittadello F, Zulian F.
        A preliminary disease severity score for juvenile systemic sclerosis.
        Arthritis Rheum 2012 Dec; 64(12):4143-50. DOI: 10.1002/art.34652.
      • Caron M, Hudson M, Baron M, Nessim S, Steele R; Canadian Scleroderma Research Group.
        Longitudinal study of renal function in systemic sclerosis.
        J Rheumatol 2012 Sep;39(9):1829-34. doi: 10.3899/jrheum.111417
    • Li SC,Torok KS, Pope E, Dedeoglu F, Hong S, Jacobe HT, Rabinovich CE, Laxer RM, Higgins GC, Ferguson PJ, Lasky A, Baszis K, Becker M, Campillo S,Cartwright V, Cidon M, Inman CJ, Jerath R, O'Neil KM, Vora S, Zeft A, Wallace CA, Ilowite NT, Fuhlbrigge RC; Childhood Arthritis and Rheumatology Research Alliance (CARRA) Localized Scleroderma Workgroup.
      Development of consensus treatment plans for juvenile localized scleroderma: a roadmap toward comparative effectiveness studies in juvenile localized scleroderma.
      Arthritis Care Res (Hoboken) 2012 Aug;64(8):1175-85. doi: 10.1002/acr.21687.